Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Malignant effusions: diagnostic evaluation and therapeutic strategy.

× No keyword cloud information.

11 in total

1. Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.

Authors: Do-Sim Park; Ki-Eun Hwang; Hyeok Shim; Byoung-Ryun Kim; Keum-Ha Choi; Seong-Hoon Park; Seok-Don Park; Eun-Taik Jeong; Hak-Ryul Kim
Journal: Clin Exp Metastasis Date: 2011-11-02 Impact factor: 5.150

2. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.

Authors: Katsuhiro Masago; Daichi Fujimoto; Shiro Fujita; Akito Hata; Reiko Kaji; Kyoko Ohtsuka; Chiyuki Okuda; Jumpei Takeshita; Nobuyuki Katakami
Journal: Mol Clin Oncol Date: 2014-11-19

Review 3. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors: Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal: Curr Oncol Rep Date: 2013-06 Impact factor: 5.075

4. Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion.

Authors: Yoon Mi Shin; Jieun Yun; Ok-Jun Lee; Hye-Suk Han; Sung-Nam Lim; Jin Young An; Ki Hyeong Lee; Ki Man Lee; Kang Hyeon Choe
Journal: Cancer Res Treat Date: 2014-04-22 Impact factor: 4.679

5. The Exploration of Peptide Biomarkers in Malignant Pleural Effusion of Lung Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.

Authors: Jing Xu; Bin Xu; Chuanhao Tang; Xiaoyan Li; Haifeng Qin; Weixia Wang; Hong Wang; Zhongyuan Wang; Liangliang Li; Zhihua Li; Hongjun Gao; Kun He; Xiaoqing Liu
Journal: Dis Markers Date: 2017-03-13 Impact factor: 3.434

6. Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer.

Authors: Ning Li; Shaohui Liu; Mingjiao Sun; Wei Chen; Xiaogang Xu; Zhu Zeng; Yemin Tang; Yongquan Dong; Alex H Chang; Qiong Zhao
Journal: Transl Oncol Date: 2017-11-10 Impact factor: 4.243

7. Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients.

Authors: Wenxian Wang; Xiaowen Jiang; Yiping Zhang; Yong Song; Zhengbo Song
Journal: J Thorac Dis Date: 2019-09 Impact factor: 2.895

8. Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions.

Authors: Do-Sim Park; Dong Kim; Ki-Eun Hwang; Yu-Ri Hwang; Chul Park; Chang-Hwan Seol; Kyung-Hwa Cho; Byoung-Ryun Kim; Seong-Hoon Park; Eun-Taik Jeong; Hak-Ryul Kim
Journal: Yonsei Med J Date: 2013-03-01 Impact factor: 2.759

9. Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma.

Authors: Hsuan-Heng Yeh; Wen-Tsan Chang; Kuang-Chu Lu; Wu-Wei Lai; Hsiao-Sheng Liu; Wu-Chou Su
Journal: PLoS One Date: 2013-09-27 Impact factor: 3.240

10. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.

Authors: Meng-Feng Tsai; Tzu-Hua Chang; Shang-Gin Wu; Hsiao-Yin Yang; Yi-Chiung Hsu; Pan-Chyr Yang; Jin-Yuan Shih
Journal: Sci Rep Date: 2015-09-04 Impact factor: 4.379